Erlotinib HCl APIs from Loncom Pharma are instrumental in crafting treatments for non-small cell lung cancer and pancreatic cancer. By inhibiting the epidermal growth factor receptor tyrosine kinase, these APIs effectively block the growth of cancer cells, contributing to improved patient outcomes.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
